Edison Oncology Announces Treatment of First Patient in Orotecan® (irinotecan HCI oral solution) Phase I/IIa Clinical Trial for Patients with Recurrent Pediatric Solid Tumors Feb 17, 2022 • 9:00am EST
Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial Sep 30, 2021 • 7:10am EDT